Gentry Leesa 4

What Happened
Leesa Gentry, Chief Clinical Officer of RenovoRx, was granted stock options covering 128,550 shares on April 3, 2026. The grant has no immediate cash value to the reporting person (acquisition price reported as $0). The options consist of 66,954 incentive stock options (ISOs) and 61,596 non-qualified stock options (NQSOs). Vesting occurs monthly over four years (1/48 per month) with no cliff, vesting effective from January 1, 2026; the options become fully vested on January 1, 2030 and expire April 3, 2036.

Key Details

• Transaction date: April 3, 2026; Form 4 filed April 7, 2026 (timely under SEC two-business-day rule).
• Grant size: 128,550 options (66,954 ISOs; 61,596 NQSOs). Reported acquisition price: $0 (derivative award).
• Vesting: Monthly at 1/48 per month, vesting start date January 1, 2026; fully vested January 1, 2030.
• Exercisability condition: Options will only become exercisable if there is an effective registration statement covering the underlying shares.
• Shares owned after transaction: Not specified in this filing.
• Footnote: Grant approved by the Compensation Committee (see footnote F1). No tax-withholding, 10b5-1 plan, or sale reported.

Context
This is a compensation-related option grant (an award), not a purchase or sale of existing shares. Because these are options, they do not represent immediate share ownership or cash proceeds until (1) the company has an effective registration statement permitting exercise and sale, and (2) the options are exercised. Such grants are common for executive compensation and are informational rather than direct market bets.